

통풍의 약물치료

Medical Treatment of Gouty Arthritis

134

Min Chan Park, M.D. · Soo - Kon Lee, M.D.

Department of Internal Medicine

Yonsei University College of Medicine, Severance Hospital

E - mail : mcpark@yumc.yonsei.ac.kr · sookonlee@yumc.yonsei.ac.kr

40 ~ 50

Abstract

Gout is a heterogenous group of diseases resulting from monosodium urate(MSU) crystal deposition in tissues or from supersaturation of uric acid in extracellular fluids. Clinical manifestations include recurrent attacks of articular and periarticular inflammation; accumulation of articular, osseous, soft tissue, and cartilagenous crystalline deposits; uric acid calculi in urinary tract; and interstitial nephropathy with renal function impairment. Gout almost always can be treated successfully and without complications. Therapeutic goals include terminating acute attack; providing rapid, safe relief of pain and inflammation; averting future attacks; and preventing such complications as formation of tophi, renal stones, and destructive arthropathy. Treatment of gout can be challenging, given that the disease frequently presents in association with other disorders; patient compliance can be difficult to achieve and the effectiveness and safety of therapies can vary widely from patient to patient. However, with early intervention, careful monitoring, and patient education, the prognosis is excellent.

Keywords : Gouty arthritis; Hyperuricemia; Medical treatment

: ; ;

가

(colchicine),
(nonsteroidal antiinflammatory drugs, NSAIDs), (glucocorticoids)
(adrenocorticotropic hormone, ACTH)

colchicine allopurinol, pro-

benecid (antihyperuricemic agents)

NSAIDs 1

, indomethacin 가

naproxen, ibuprofen, sulindac, piroxi-

cam NSAIDs

Colchicine

NSAIDs

Colchicine

48

colchicine

48

NSAIDs

NSAIDs 가

75~85%

colchicine 0.6 mg 1

NSAIDs

65

colchicine

COX - 2

(celecoxib, rofecoxib)

가

COX - 2

NSAIDs

6.0 mg

colchicine

NSAIDs

1 mg

2 mg

6

1 mg 가

가 (2).

가 (1).

Colchicine NSAIDs가 가

colchicine

0.6 mg

1

2

ACTH

pred-

allopurinol

nisolone 20~40 mg 3, 4

1~2

. ACTH

cosyntropin 40~80 IU 1 6~12 (3).

40 IU 가

10~40 mg

triamcinolone 2~10 mg

dexamethasone

24

가

1. Allopurinol

all-

가

opurinol

가

. Allopurinol 1 300 mg

1 100 mg

. Allopurinol

가

가

allopurinol

6.0 mg/dL

가

. Allopurinol

6~12

(hypersensitivity syndrome)

가

(4).

2. (Uricosuric Agents) 가

50~60 mL/

1

가

. Salicylates

, 65

cyclosporine

Probenecid sulfinpyrazone 가

50%

probenecid 1 500 mg

1,000~2,000 mg

3,000 mg

가

가

sulfinpyrazone 50 mg 1 2

800 mg

가

NSAIDs colchicine

Probenecid

가

ACTH

가

benzbromarone

(pred-

nisolone 40~60 mg/)

allopuri-

nol

azathioprine

allopurinol

(5).

가

colchicine

. NSAIDs



1. Putterman C, BenChetrit E, Caraco Y, Levy M. Colchicine intoxication : Clinical pharmacology, risk factors, features, and management. *Semin Arthritis Rheum* 1991 ; 21 : 143 - 55
2. Sandler DP, Barr R, Weinberg CR. Nonsteroidal antiinflammatory drugs and the risk for chronic renal failure. *Ann Intern Med* 1991 ; 115 : 165 - 72
3. Wortmann RL. Gout and hyperuricemia. *Curr Opin Rheumatol* 2002 ; 14 : 281 - 6
4. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reaction. *Arthritis Rheum* 2001 ; 44 : 231 - 8
5. Perez - Reuz F, Alonso - Ruiz A, Calabozo M, Duruelo J. Treatment of gout after transplantation. *Br J Rheumatol* 1998 ; 37 : 580